Healthcare AI agents funding tracker (200+ deals)

Our funding tracker covering the healthcare AI agents market

Below is the table listing all the deals. You can find our methodology at the end of this page.

If you want a deeper understanding of the market and its current dynamics, get our healthcare AI agents market report.

How much funding have healthcare AI agents actually raised?

Healthcare AI agent startups have raised at least $6.6B across 281 qualifying deals since January 2024.

That capital is spread across 190 independent startups whose products complete multiple connected clinical or administrative tasks. They include agents that coordinate care, book visits, document encounters and carry out billing or authorization work. It does not include every AI model used in medicine or every chatbot that answers patients' questions.

Abridge is the clearest example of the market's scale. We count at least $700M raised by Abridge across 4 recent financings, including its $300M Series D+ in June 2025, without its earlier rounds. At a different end of the workflow, Candid Health raised a $120M Series D+ in July 2026 for autonomous revenue-cycle management. Latent Health raised an $80M Series A in March 2026 for medication access. The money is spread across different hospital workflows. Most rounds look nothing like Abridge's biggest check.

How big is a normal healthcare AI agent funding round?

A normal healthcare AI agent funding round is far smaller than the nine-figure checks in the headlines.

The median round across our coverage is $11.0M, compared with the largest individual deal of $300M. The busiest financing bracket was $5M to under $20M, containing 112 deals. Another 69 deals were under $5M, while 53 fell between $20M and under $50M. The bulk of deals sit well below the famous giant rounds.

Founders comparing their raise with a famous deal need that context. Abridge's $150M Series C in February 2024 was a significant financing for a company already selling clinical documentation to health systems. Prosper AI's $30M Series A in June 2026 backs a different expansion path through scheduling, insurance and billing. A small agent startup making its first deployment should not treat either as its normal raise. The median better describes completed rounds, although a startup's stage still matters.

Does a typical healthcare AI agent startup raise millions?

The typical healthcare AI agent startup raises far less than Abridge and the other standout companies.

The median total capital per company recorded in the window is $15M. By comparison, the most-funded startup in this window, Abridge, raised at least $700M. Hippocratic AI raised $337M across 4 recorded rounds, and Ambience Healthcare raised $313M across 2. Those are examples of investors backing differentiated products, not the funding experience of a representative startup.

The difference between a company total and a single round is especially important. Abridge's total includes multiple closings over time, so it would be wrong to credit the full amount to its $300M Series D+ in June 2025 alone. Likewise, Hippocratic AI's patient-facing agents and Ambience's documentation-and-coding system pursued separate clinical buyers and use cases. Our company totals describe financing inside this coverage window, not a claim about every dollar each company raised since incorporation. A useful comparison is a startup at the same stage, not the biggest name in the sector.

Are most healthcare AI agent funding rounds still under $50M?

Most healthcare AI agent rounds are still below $50M, even though giant deals dominate the headlines.

Our deal-size distribution records 69 disclosed deals under $5M, 112 deals from $5M to under $20M, and 53 deals from $20M to under $50M. Only 13 disclosed deals were $100M or more. There were also 29 deals in the $50M-to-under-$100M bracket. Most of the activity sits in mid-sized checks, not in a few giant rounds.

At the smaller end, founders often target one workflow, such as patient intake or follow-up calls. At the larger end, companies may be supporting more connected tasks across healthcare organizations. Prosper AI described its scheduling-to-billing platform after a June 2026 financing, while Suki said in October 2026 it was moving beyond documentation into reasoning and revenue operations. The checks support different tasks, from scheduling to billing, rather than one generic type of healthcare AI.

Are a few giant rounds taking most healthcare AI agent funding?

A small group of big healthcare AI agent rounds absorbs a huge share of the money raised.

We identified 34 rounds above $50M across the full coverage period. They represented 12% of deals and raised $3.4B. By contrast, removing those rounds leaves at least $3.2B. For an even stricter threshold, there were 11 rounds above $100M, raising $1.8B. The threshold is important: a round exactly equal to $100M belongs in the $100M-or-more bucket but not the set above $100M.

Abridge's $300M Series D+ in June 2025, Ambience Healthcare's $243M Series C in July 2025 and Forus's $150M Series C in September 2026 show how individual announcements can change the apparent shape of an annual chart. Yet the remaining capital is too large to dismiss as incidental. There is a broad market for ordinary rounds, plus a small group of unusually large raises. A big raise still proves nothing about profits or market control.

Is healthcare AI agent funding going to the same few startups?

A few healthcare AI agent startups raise exceptional sums, but funding reaches many other companies too.

Abridge leads funding raised within the coverage window, at least $700M across 4 rounds. Hippocratic AI followed with $337M across 4, while Ambience Healthcare recorded $313M across 2 and Forus $275M across 2, both in 2026. Meanwhile, our market includes 190 funded companies, and 118 of them completed only one qualifying financing during the window. No single startup accounts for all those deals.

These top businesses also do different work. Abridge automates clinical documentation connected to medical and financial processes. Hippocratic AI develops patient-facing healthcare agents, including follow-up conversations. Ambience Healthcare emphasizes documentation, coding and clinical documentation integrity for health systems. Investors have repeatedly backed several different hospital tasks. The biggest fundraising totals tell us nothing about which company has the most users or the best outcomes.

How much funding has Abridge raised recently?

Abridge has raised more than any other healthcare AI agent startup in recent years, at least $700M across 4 rounds.

The individual financings include Abridge's $150M Series C in February 2024, its $250M Series D+ in February 2025 and its $300M Series D+ in June 2025. The company also raised again in June 2026, with no stage or amount made public. We do not turn that undisclosed amount into an invented dollar figure, which is why the company total is a minimum.

Abridge's public releases explain why the market has paid attention. The February 2025 announcement described large health-system deployments and a contextual reasoning engine, while the June 2025 announcement linked clinical conversations with documentation and reimbursement workflows. Abridge is selling more than transcript generation. That fundraising total is no substitute for revenue or audited customer results. It establishes the size and persistence of the capital commitment within this period.

Are AI medical scribes taking most healthcare AI agent funding?

Not most, but AI medical scribes have taken the largest single share of healthcare AI agent funding, and other categories are getting serious backing too.

Across the coverage window, the category recorded 53 deals involving 32 companies and raised at least $2.1B, representing 32% of disclosed capital. Provider operations had more deals, and revenue-cycle agents attracted substantial funding as well. So documentation gets far more than its share of the money, with only 19% of the deals, but it isn't the only category investors back.

The largest documentation platforms now do more than write notes. Ambience Healthcare's $243M Series C in July 2025 backed clinical notes, coding and documentation integrity, and Suki's $90M Series D+ in October 2026 supported movement into clinical reasoning and revenue-cycle tasks. Heidi Health's $100M Series C in September 2026 funded a similar broadening from note generation toward supervised actions. Investors are backing tools that move from notes to coding and related work.

The table below shows healthcare AI agents categories by recorded disclosed capital.

Category	Deals	Companies	Capital	Share of capital
Clinical Documentation Agents	53	32	$2.1B+	32%
Provider Operations Agents	63	46	$1.0B+	15%
Revenue Cycle Agents	52	34	$1.0B+	15%
Prior Authorization Agents	23	16	$802M	12%
Patient Communication & Navigation Agents	30	16	$682M+	10%
Care Coordination Agents	28	22	$542M	8%
Patient Access & Scheduling Agents	31	23	$431M	6%

Can healthcare AI agents raise big money without writing notes?

Healthcare AI agents for billing, authorization and patient access can raise major rounds without generating clinical notes.

Revenue cycle agents accounted for 52 deals and at least $1.0B across the window. Prior authorization agents attracted 23 deals and $802M, while patient access and scheduling agents recorded 31 deals and $431M. Those sums demonstrate that healthcare-agent financing is broader than ambient dictation and automatic clinical summaries.

Candid Health's $120M Series D+ in July 2026 targets the revenue cycle, and Charta Health's $55M Series B in November 2026 helps providers and payers read charts consistently before claims are issued. Latent Health's $80M Series A in March 2026 addresses medication access. These products make the business question concrete: can software complete labor-intensive tasks across multiple systems and with proper oversight? The numbers show where investors put money, not which product will win. Hospitals may end up using several of these systems together.

Are hospital operations AI agents actually getting funded?

AI agents for hospital operations have attracted substantial investment across many independent startups.

This category led the full market by deal count, with 63 financings across 46 companies, and attracted at least $1.0B. The median round was $11M. In short, lots of different startups are raising, and some have raised big sums to grow. The category includes staffing, capacity management, pharmacy operations and other work that makes clinical organizations function.

Qventus described hospital operations assistants in a January 2025 investment announcement, and TJM Labs described pharmacy-native agents managing prescription intake, refills and patient communication in July 2026. Vitalize's $31M Series A in October 2026 targeted staffing and scheduling. These are different operational settings but share the need to move work between staff, records and scheduling systems. We cannot verify every deployment from funding announcements. But these are established, funded use cases beyond isolated pilots.

Is AI patient scheduling getting less money than billing?

Patient-scheduling AI agents have raised less money than healthcare AI billing startups.

Patient access and scheduling recorded 31 deals, 23 companies and $431M. Revenue cycle recorded 52 deals, 34 companies and at least $1.0B. The median round differed too: a $5M median in patient access compared with $15M for revenue cycle. Scheduling gets patients into care. Revenue-cycle software helps providers get paid.

Assort Health's $120M Series C in June 2026 demonstrates that patient access can generate a very large check, especially when a product expands across referrals, appointments and related tasks. Candid Health's $120M Series D+ in July 2026 shows a similar upper-end financing in the billing category. Large checks exist in both categories despite the gap in total funding. Investors nonetheless backed more billing rounds and put more money into them.

Are prior authorization and care coordination still niche bets?

Prior authorization and care coordination AI agents have attracted serious venture money, despite targeting narrower workflows.

Prior authorization agents recorded 23 deals across 16 companies, with $802M in disclosed capital. Care coordination agents recorded 28 deals across 22 companies and raised $542M. They solve different bottlenecks: authorization handles permissions and coverage requirements, while coordination covers handoffs, referrals and patient follow-through.

Forus's $125M Series B in May 2026 and $150M Series C in September 2026, along with Latent Health's $80M Series A in March 2026, illustrate substantial capital committed to medicine-access processes. Tennr's $101M Series C in June 2025 targeted referral coordination. CMS's January 2024 interoperability and authorization rule gives important external context: payers face new administrative and technology requirements, although drug authorizations are excluded from major provisions of that rule. The policy gives these products urgency, although the deals cannot tell us whether it caused the investments. Both niches are getting meaningful funding, whatever motivated individual investors.

Can patient-facing AI agents attract major funding rounds?

Patient-facing AI agents can raise major venture rounds, though a few larger companies shape the category’s total.

The category comprises 30 deals across 16 startups and at least $682M in recorded funding. It is much more than generic call-center chat: qualifying products complete connected patient workflows such as outreach, care navigation or follow-up. The median round is $10M, which sits well below the category's largest individual financings.

Hippocratic AI is a prominent example. The company announced a $141M Series B in January 2025 and a $126M Series C in November 2025 for patient-facing generative AI agents. Its releases describe healthcare interactions that need careful oversight and safety evaluation, not unrestricted autonomous clinical treatment. More modest examples include Confido Health's $12M Series A in October 2026 and Parakeet Health's $10M Series A in October 2026. A few very large raises can make patient communication look better funded than most of its startups really are.

Do healthcare AI agent startups make it beyond Series A?

Far fewer healthcare AI agent startups reach Series C or D+ than raise seed or Series A money.

We counted 127 Seed rounds and 88 Series A rounds across the window. Series B had 28 rounds, Series C had 15 and Series D+ had 7. Among deals with a named stage, early-stage rounds represented 80% of deals but only 38% of disclosed capital. Later-stage rounds captured 62% of disclosed capital. Big checks are much rarer than entry-stage rounds.

Some companies really do reach those later rounds. Abridge's $300M Series D+ in June 2025 and Suki's $90M Series D+ in October 2026 show healthcare AI platforms attracting major institutional support. Candid Health's $120M Series D+ in July 2026 shows the same pattern outside documentation. But these later rounds remain rare, and companies do not always follow a neat sequence.

The table below shows deal activity and disclosed capital by financing stage.

Stage	Deals	Companies	Capital	Share of capital
Series A	88	85	$1.8B	27%
Series B	28	28	$1.4B	22%
Series C	15	14	$1.4B	21%
Series D+	7	5	$958M	14%
Seed	127	116	$700M+	11%
Growth Equity	5	5	$188M	3%
Unknown	11	11	$139M+	2%

How often do healthcare AI agent startups raise more than once?

Many healthcare AI agent startups raise follow-on money, but most have closed only one round in recent years.

We found 118 companies with one qualifying financing, 57 with 2 recorded rounds and 15 with 3 or more rounds during the window. Those groups represent 62%, 30% and 8% of the 190 funded companies. These are rounds closed in recent years, not each company's lifetime funding history.

Abridge's repeated raises illustrate what the upper end looks like. Assort Health also recorded several financings from an initial Seed in March 2024 through its $120M Series C in June 2026. Tandem Health progressed from a June 2024 Seed through its $100M Series B in September 2026. Those repeat raises are possible, but most founders will not follow exactly the same path. Many companies have appeared only once in the covered period, either because they are young, raised before our window or have not yet secured another round.

Are investors abandoning first-time healthcare AI agent founders?

Healthcare AI agent follow-on rounds account for most disclosed capital, even though new startups keep entering the market.

We classified 77 financings as first rounds, worth at least $517M, against 143 follow-on financings worth at least $5.4B. Follow-ons represented 51% of all deals and 81% of disclosed capital. First financings represented 27% of deals and 8% of disclosed capital. The other 61 deals, 22% of the total, stay unclassified: we call a round a follow-on only when an earlier equity round is in our records, and a first financing only when the source says so.

Established platforms keep returning for larger rounds, which raises the follow-on total. Abridge, Candid Health and Suki all have products that extend across complex clinical or administrative tasks. But the data alone does not reveal each company's spending, profitability or exact use of proceeds. Existing funded companies raised most of the money. Their exact spending plans cannot be read from the deal counts.

How long do healthcare AI agent startups wait between rounds?

Healthcare AI agent startups that raise again often do so within months, though the public histories are incomplete.

Across measured intervals between successive financings, the median was 13 months. In total, 41% of observed gaps were under 12 months, 60% were under 18 months and 73% were under 24 months. These percentages describe gaps between rounds for the same company, not the proportion of all startups that successfully raised another round.

Coverage for this measure is 52% of relevant histories, which should temper its use as a forecast. Funding can be announced long after the close, and some companies combine instruments or keep capital confidential. The public sequence of Abridge's February 2024, February 2025 and June 2025 financings shows that rapid successive rounds are possible at scale. Assort Health's financing progression provides another concrete example. This is a record of past funding intervals, not a promise about the next one.

Do healthcare AI agent startups have to be older to raise big?

Healthcare AI agent startups getting the largest checks tend to be older than those raising smaller rounds.

Median company age at the recorded round was 2 years, while companies raising above $50M had a median age of 5 years. For rounds under $5M, the median company age was 2 years. The market has a very recent cohort: 85% of funded companies were founded since 2020, and 70% since 2022.

The difference shows up when we compare small and big rounds. A new business may receive a small initial check while it builds access to medical records and proves one concrete workflow. Companies such as Abridge and Ambience Healthcare have moved beyond that starting point through major deployments and expanded products, as their 2025 announcements describe. Being older does not prove a product works better. We can measure startup age, but we cannot tell from a check why an investor approved it.

Is healthcare AI agent funding mostly a US story?

US healthcare AI agent startups account for most of the deals and an even larger share of the money.

Across the window, the United States accounted for 220 deals involving 147 companies, raising at least $5.8B. That represented 78% of transactions and 87% of disclosed capital. Europe, by comparison, recorded 38 deals and $505M. Asia-Pacific recorded 10 deals and $201M. A handful of large American closings can change the global total.

That concentration also reflects the business problems being targeted. Revenue-cycle claims, prior authorization and hospital workflows are especially prominent in American company descriptions. Candid Health's July 2026 financing and Latent Health's March 2026 announcement both focus on demanding U.S. administrative processes. Still, headquarters are not the same as customer geography or investor location. A startup can be based abroad and sell into American providers, and American companies may operate internationally. We assign locations by headquarters, not by where the software is used.

Are European healthcare AI agents getting serious funding?

European healthcare AI agent startups have attracted substantial rounds, though US fundraising still dwarfs the region.

Europe accounted for 38 deals across 27 startups and $505M since January 2024, representing 14% of deals and 8% of disclosed capital. Its median round was $5.5M, compared with $13M in North America. European startups are raising money, just in smaller typical rounds.

Tandem Health's $100M Series B in September 2026 was a significant European round, and the company said its AI clinic software operates across several health systems and markets. Vocca's $20M Series A in October 2026 in France illustrates investment in localized patient-access voice agents. Sweden and France are not the only sources of activity, but the examples show different models rather than one isolated European success. Europe has credible startups, but it still takes a small share of global funding.

Does healthcare AI agent funding come in bursts?

Healthcare AI agent funding happens throughout the year, but large rounds make some months far busier in dollar terms.

Across 34 completed months, the median month contained 8 deals and $154M in disclosed funding. There was no completed month with no recorded deal. October 2025 had the highest monthly deal count, with 16 transactions, whereas June 2025 had the highest disclosed monthly capital total, $663M. The busiest month by transactions was therefore not the month with the most money.

The difference is explained by which financings closed, not just how many. Abridge's $300M Series D+ in June 2025 contributed to that month's high capital total. October 2025 contained numerous smaller transactions across different workflows. September 2026 then became another visible funding burst with Forus, Heidi Health and Tandem Health raising substantial rounds. One busy month does not mean the next will be busy. Deals occur regularly, but the funding dollars are far less evenly distributed.

Are healthcare AI agents being used in hospitals or just demoed?

Healthcare AI agent companies now advertise tools that finish real hospital tasks, although investor checks do not prove clinical results.

The business case is visible in several very different examples. Abridge's company announcements connect visit documentation to clinical and billing workflows. Candid Health describes an autonomous revenue-cycle platform handling the path to reimbursement. TJM Labs describes agents that manage pharmacy prescription intake, refills and patient communication. The companies want to finish tasks that hospitals currently pay staff to do.

Epic is also building similar tools inside hospital records. In September 2026, Epic said 25 health systems attended its Agent Factory build-a-thon to create agents for concrete hospital tasks. Epic's September 2026 announcement described hospitals using Agent Factory to build agents that act inside the electronic health-record environment. That raises a meaningful question for independent vendors: can they offer automation that is more reliable or easier to deploy than software already embedded in a hospital? Funding tells us which products attracted investors. It cannot verify safety, accuracy or customer results.

So, what does healthcare AI agents funding look like across the full deal history?

Healthcare AI agent funding has grown into a multibillion-dollar market, but a handful of startups still attract its biggest checks.

Abridge leads cumulative funding raised within the covered window, while the most active disclosed lead investor is Andreessen Horowitz, which led 10 recorded rounds. The market's median deal is far smaller than its largest announcement, and far fewer startups make it past Series A. The United States dominates dollars, but viable product categories extend well beyond notes and well beyond American headquarters.

The market supports repeat rounds and specialized products, but most startups are still young. The tougher question is which workflows get funded repeatedly and who can attract the rare giant check.

The table below shows what we found.

Question	Answer
Is healthcare-agent funding only an emerging experiment?	Healthcare-agent funding has become far larger than a small experiment. We recorded 281 qualifying deals during the full coverage period. Those investments reached startups solving different clinical and administrative problems.
Are giant funding announcements representative of typical rounds?	Huge healthcare-agent rounds are exceptions rather than the typical experience. The median disclosed round was $11M since January 2024. Founders should compare with similar companies, not just the biggest names.
Does one startup account for every big deal?	Abridge is a standout, but funding reaches many other healthcare startups. It raised at least $700M during our full coverage period. Those rounds cover only one part of a much larger market.
Are ordinary startups also receiving financing today?	Ordinary healthcare-agent financing covers a wide range of middle-sized checks. The $5M-to-under-$20M bracket contained 112 deals in the full window. Giant announcements give a distorted impression of what most startups raise.
Do the biggest financings consume most available capital?	The biggest healthcare-agent rounds absorb a huge share of disclosed funding. Rounds above $50M raised $3.4B during the full window. Plenty of capital still went to companies raising smaller checks.
Is documentation the only investable healthcare workflow?	Investors fund far more than documentation and note-taking tools today. Revenue-cycle agents raised at least $1.0B during the coverage period. Billing and authorization can attract large rounds without writing clinical notes.
Do many startups make it past Series A?	Healthcare-agent startups can reach later stages, but few actually do. Series C accounted for 15 deals since January 2024. Most successful rounds happen earlier in a company’s funding history.
Are repeat fundraises normal for every startup?	Repeated funding is possible, but many healthcare-agent startups raise only once. We counted 118 companies with one qualifying round in the window. Reaching later rounds remains a selective outcome, even among funded startups.
Can founders rely on instant follow-up financing?	Healthcare-agent startups cannot assume the next check will come quickly. The median observed gap between rounds was 13 months. Some companies raise faster, but public funding histories are incomplete.
Are funded companies mostly already decades old?	Most healthcare-agent startups are young when they receive venture backing. The median company age at financing was 2 years. Bigger rounds tended to go to startups that had existed longer.
Is global healthcare-agent capital evenly spread geographically?	The US remains dominant in healthcare-agent funding across our full window. American startups took 87% of all disclosed capital recorded. European founders are raising money too, but in smaller typical checks.